Issue:
A pharmaceutical client approached DMS to create a benefit risk assessment of their target product relative to current treatment modalities in the marketplace for patients with atherothrombotic disease.
Solution:
- We constructed a benefit risk assessment (BRA) based on a thorough review of the clinical trial data for the target product as well as results from comparator trials. A table detailing calculated relative risk (RR), relative risk reduction (RRR), absolution risk reduction (ARR), number needed to treat (NNT) and number needed to harm (NNH) pulled from the clinical trials was generated. Benefit risk was assessed using NNT/NNH ratios.
- The benefit risk assessment showed that the target product had a positive benefit to risk profile across various ‘high risk’ sub-populations when compared to standard comparators. Some of the data from this analysis was used to help inform the construction of economic models to support the target product market access.
- Elements of the BRA report and the final economic models were used by the client in their engagement with prospective clients.
